CD30-directed therapy using brentuximab vedotin is effective in relapsed Hodgkin lymphoma and ALCL,62,63 a strategy that may be useful in patients with CD30+RANBP2-ALK eIMS. This evidence concerns the gene TNFRSF8 and anaplastic large cell lymphoma.